Boston Scientific Expects PMA Supplement To Further Delay SOX Re-Launch
This article was originally published in The Gray Sheet
Executive SummaryBoston Scientific likely will submit data to FDA in the form of a premarket approval application supplement for the relaunch of the Nir-On-Ranger with SOX securement system, leading analysts to envisage a second-half 1999 return to market for the pre-mounted coronary stent system.
You may also be interested in...
While disappointing result will probably put an end to single-drug development plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.